Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -120.40% is 138% below its 4-year average of -50.56%, around the middle of its 4-year range (-252.55%–-18.36%).
As of the fiscal period ended Tuesday, June 30, 2026. 79.82% below its 12-month average of -66.95%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -120.40%.
RETURN ON EQUITY (ROE)
-120.40%
RETURN ON EQUITY (ROE) AVG TTM
-66.95%
RETURN ON EQUITY (ROE) AVG 3Y
-70.02%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-79.82%
CURRENT VS 3Y AVG
-71.94%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-38.25%
median of 444 covered companies
CURRENT VS SECTOR MEDIAN
-214.76%
vs the sector median at left
Context Therapeutics Inc.
Market Cap
$31.14M
Return on Equity (ROE)
-120.40%
TTM Avg
-66.95%
3Y Avg
-70.02%
5Y Avg
N/A
Market Cap
$31.11M
Return on Equity (ROE)
-132.18%
TTM Avg
-94.77%
3Y Avg
-38.62%
5Y Avg
-46.78%
Market Cap
$30.81M
Return on Equity (ROE)
-86.96%
TTM Avg
-27.78%
3Y Avg
5.60%
5Y Avg
57.54%
Market Cap
$32.55M
Return on Equity (ROE)
N/A
TTM Avg
333.35%
3Y Avg
376.86%
5Y Avg
270.78%
Market Cap
$31.35M
Return on Equity (ROE)
N/A
TTM Avg
29.33%
3Y Avg
173.42%
5Y Avg
64.03%
Market Cap
$28.43M
Return on Equity (ROE)
-124.64%
TTM Avg
-100.64%
3Y Avg
-80.07%
5Y Avg
-67.08%
Market Cap
$33.79M
Return on Equity (ROE)
-238.24%
TTM Avg
203.84%
3Y Avg
55.01%
5Y Avg
16.87%
Market Cap
$33.85M
Return on Equity (ROE)
-44.50%
TTM Avg
-16.33%
3Y Avg
-36.34%
5Y Avg
-33.52%
Market Cap
$29.24M
Return on Equity (ROE)
-111.81%
TTM Avg
-29.10%
3Y Avg
-257.52%
5Y Avg
159.26%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Context Therapeutics Inc. (CNTX) | $31.14M | -120.40% | -66.95% | -70.02% | N/A |
| CervoMed Inc. (CRVO)vs › | $31.11M | -132.18% | -94.77% | -38.62% | -46.78% |
| Baird Medical Investment Holdings Limited (BDMD)vs › | $30.81M | -86.96% | -27.78% | 5.60% | 57.54% |
| EUDA Health Holdings Limited (EUDA)vs › | $32.55M | N/A | 333.35% | 376.86% | 270.78% |
| BeyondSpring Inc. (BYSI)vs › | $31.35M | N/A | 29.33% | 173.42% | 64.03% |
| aTyr Pharma, Inc. (ATYR)vs › | $28.43M | -124.64% | -100.64% | -80.07% | -67.08% |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.79M | -238.24% | 203.84% | 55.01% | 16.87% |
| Grace Therapeutics, Inc. (GRCE)vs › | $33.85M | -44.50% | -16.33% | -36.34% | -33.52% |
| GridAI Technologies Corp. (GRDX)vs › | $29.24M | -111.81% | -29.10% | -257.52% | 159.26% |
| Accuray Incorporated (ARAY)vs › | $36.26M | -117.97% | -59.96% | -42.92% | -31.82% |
ROE
-120.4%
ROA
-99.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -120.40% |
| 2026-03-31 | -77.06% |
| 2025-12-31 | -59.73% |
| 2025-09-30 | -36.13% |
| 2025-06-30 | -41.44% |
| 2025-03-31 | -30.37% |
| 2024-12-31 | -28.05% |
| 2024-09-30 | -35.96% |
| 2024-06-30 | -18.36% |
| 2024-03-31 | -252.55% |
| 2023-12-31 | -201.87% |
| 2023-09-30 | -112.87% |
| 2023-06-30 | -78.03% |
| 2023-03-31 | -61.62% |
| 2022-12-31 | -42.68% |
| 2022-09-30 | -37.75% |
| 2022-06-30 | -28.71% |
| 2022-03-31 | -28.64% |
| 2021-12-31 | -21.66% |
